Futura Medical chief executive James Barder caught up with Proactive Investor's Stocktube to discuss analysis they’ve been carrying out on the results of their clinical study on the erectile dysfunction drug MED2002.
''The first thing to say is that there's been nothing dramatically different to what we originally saw ... but the key finding from it is that we think there's a great opportunity for us to move forward with two different doses - the current dose and a higher dose''.
Barder went on to say ''All existing treatments for erectile dysfunction, all the oral tablets, have at least two if not three doses which enables the patient to titrate to the level which they feel is appropriate for them''.
''We've had very good efficacy data on the mild and the mild-to-moderate. On the moderate there's some encouraging signs but it certainly wasn't strong enough to achieve the benchmark we're looking for in clinical excellence so we believe there's a great opportunity at a higher dose to do that.''
Barder added: ''Today we're announcing that moving forward on the remaining clinical program we will have two different doses - the current dose and a higher dose which we hope will be more effective on the moderate and severe ED patients.''
Futura's also recruited Ken James, currently a non-executive director, to oversee its research and development efforts.
James is the former head of consumer healthcare R&D at GlaxoSmithKline, where he brought more than 200 innovative products to market.